Clinical Trials

-

 

Your Gateway to Clinical Trials

Understanding the Investigational New Drug Application Process
By Visnova Consultancy

In drug development, few milestones are as pivotal as the submission of an Investigational New Drug (IND) application. It represents the formal request to begin human clinical trials in the United States and marks the transition from preclinical research to first-in-human studies.

At Visnova, we guide organizations through this critical phase, ensuring regulatory readiness, scientific clarity, and strategic foresight.

🧬 What Is an Investigational New Drug (IND)?

An IND is a regulatory submission filed with the U.S. Food and Drug Administration (FDA) that allows the sponsor (pharmaceutical company, academic researcher, or CRO) to legally ship an unapproved drug across state lines for use in clinical trials.

Without an active IND, no human testing can begin in the U.S., regardless of the drug’s preclinical promise.

📋 Objectives of an IND

The primary purpose of an IND is to protect the safety and rights of human subjects and to ensure that the clinical study is scientifically sound. The FDA uses this submission to:

  • Evaluate if the drug is reasonably safe for initial use in humans.

  • Ensure clinical protocols are well designed.

  • Review manufacturing information to confirm consistency and purity.

🧪 Key Components of an IND Submission

An IND includes three core areas of documentation:

1️⃣ Preclinical Data (Pharmacology & Toxicology)

  • In vivo and in vitro animal data to demonstrate the drug’s safety profile.

  • Includes dose formulation analysis, toxicokinetics, and GLP-compliant studies.

2️⃣ Chemistry, Manufacturing, and Controls (CMC)

  • Details on drug substance synthesis, formulation composition, stability, and manufacturing protocols.

  • Ensures reproducibility and quality control of the investigational product.

3️⃣ Clinical Protocol and Investigator Information

  • Proposed Phase I study protocol, including inclusion/exclusion criteria, dosing regimen, and monitoring plan.

  • Details of the clinical investigators, their qualifications, and informed consent procedures.

⏳ Types of INDs

IND TypePurpose
Commercial INDSubmitted by sponsors intending to market the drug eventually.
Research (Investigator) INDFor academic or research institutions not tied to commercial use.
Emergency INDFor urgent situations (e.g., life-threatening infections with no alternatives).
Treatment INDFor promising drugs not yet approved but used in treating severely ill patients.

🧭 IND Lifecycle: From Submission to Study Start

  1. Pre-IND Consultation (Optional) – Sponsors may seek FDA input before submitting.

  2. IND Submission – Full dossier submitted electronically (eCTD format preferred).

  3. 30-Day Review Window – The FDA has 30 calendar days to raise concerns or place a clinical hold.

  4. Study Initiation – If no hold is issued, human trials may begin after day 30.

🔍 IND and GLP: The Critical Link

Before filing an IND, preclinical studies must be conducted under GLP (Good Laboratory Practice) regulations. These include:

  • Dose formulation analysis for concentration, homogeneity, and stability.

  • Toxicity and toxicokinetic studies across multiple species.

  • Analytical method validation to ensure accurate, reproducible results.

Any data gaps, noncompliance, or weak study design can lead to a clinical hold or rejection.

🌐 IND Beyond the U.S.: A Global Perspective

While the IND is U.S.-specific, similar processes exist globally:

RegionEquivalent to IND
Europe (EMA)CTA (Clinical Trial Application)
India (CDSCO)CT-ND (New Drug Clinical Trial App)
Japan (PMDA)Clinical Trial Notification (CTN)

Each region emphasizes preclinical safety, GMP manufacturing, and ethics approval as prerequisites.

✅ Best Practices for IND Success

  • Start early with regulatory strategy.

  • Invest in robust CMC documentation to avoid delays.

  • Conduct GLP-compliant toxicology and formulation studies.

  • Engage in FDA pre-IND meetings to clarify expectations.

  • Use eCTD-compliant software for submission formatting.

Comments

Post a Comment

Popular posts from this blog

Organization Process

-
Understanding the Organizational Process in a GLP-Compliant Lab In the context of Good Laboratory Practice (GLP) and Contract Research Organizations (CROs), the term "organizational process" holds significant weight. It is the foundation on which reliable, reproducible, and regulatory-compliant research is built. But what exactly does it mean? 📌 Definition : The organizational process refers to the structured system of planning, executing, monitoring, and documenting all activities within a laboratory or research setting to ensure studies meet their scientific and regulatory objectives. 🔍 Why Is It Important in GLP-CROs? In GLP environments, data integrity and accountability are non-negotiable. The organizational process ensures: ✅ Each study is pre-approved and methodically designed ✅ Roles and responsibilities are well-defined ✅ Resources are efficiently allocated ✅ Every step is documented, reviewed, and auditable 🔄 Key Components of the Organizational Process Step Wha...
Read more

What Are Complex Generics?

-
  What Are Complex Generics? The New Frontier in Affordable Innovation – By VISNOVA Consultancy In today’s pharmaceutical industry, complex generics are redefining the boundaries of generic drug development. These specialised formulations are bioequivalent to branded drugs but involve far greater technical sophistication , requiring advanced capabilities in formulation science, device integration, and regulatory compliance. 🧬 What Makes a Generic ‘Complex’? Unlike conventional generics, complex generics are harder to develop due to unique routes of administration, formulation technologies, or embedded delivery devices. Key Feature Examples Non-oral routes Inhalers, injectables, transdermal patches Complex formulation Liposomes, nanoparticle suspensions Drug-device combinations Auto-injectors, metered-dose inhalers (MDIs) Extended/controlled release Once-weekly injections, slow-release tablets Site-specific delivery Ocular, nasal, pulmonary, transdermal drugs Difficult bioe...
Read more

GLP-CRO labs

-
Introduction Good Laboratory Practice (GLP) is a quality system concerned with the organizational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived, and reported. For pharmacy students aspiring to enter the pharmaceutical industry, especially in Contract Research Organizations (CROs), understanding GLP is crucial. What is a CRO? Contract Research Organizations (CROs) are independent organizations that provide support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. CROs play a key role in analytical method development, validation, and GLP-compliant studies. The Role of GLP in Analytical Labs GLP ensures the integrity and reliability of data generated by analytical labs. Key elements include: Standard Operating Procedures (SOPs) Documentation and traceability Equipment qualification and calibra...
Read more